| Literature DB >> 34903641 |
Melinda Czeh1,2, Sina Stäble3, Stephen Krämer3,4,5,6, Lena Tepe1, Sweta Talyan7, Joana Carrelha2, Yiran Meng2, Barbara Heitplatz8, Marius Schwabenland9, Michael D Milsom10, Christoph Plass11, Marco Prinz9,12,13, Matthias Schlesner4,5, Miguel A Andrade-Navarro7, Claus Nerlov2, Sten Eirik W Jacobsen2,14,15, Daniel B Lipka3, Frank Rosenbauer16.
Abstract
Dendritic cells (DCs) are heterogeneous immune regulators involved in autoimmune diseases. Epigenomic mechanisms orchestrating DC development and DC subset diversification remain insufficiently understood but could be important to modulate DC fate for clinical purposes. By combining whole-genome methylation assessment with the analysis of mice expressing reduced DNA methyltransferase 1 levels, we show that distinct DNA methylation levels and patterns are required for the development of plasmacytoid DC and conventional DC subsets. We provide clonal in vivo evidence for DC lineage establishment at the stem cell level, and we show that a high DNA methylation threshold level is essential for Flt3-dependent survival of DC precursors. Importantly, reducing methylation predominantly depletes plasmacytoid DC and alleviates systemic lupus erythematosus in an autoimmunity mouse model. This study shows how DNA methylation regulates the production of DC subsets and provides a potential rationale for targeting autoimmune disease using hypomethylating agents.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34903641 PMCID: PMC7612220 DOI: 10.4049/jimmunol.2100624
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426